Alnylam and Collaborators Publish Research on a New Class of Chemically Modified RNAi Therapeutics that Target Two Distinct Cellular Mechanisms.
Business Wire › November 03, 2008
Linked as:
Extract
Alnylam and Collaborators Publish Research on a New Class of Chemically Modified RNAi Therapeutics that Target Two Distinct Cellular Mechanisms.
- New Findings Published in Nature Medicine Describe "3p-siRNAs," RNAi Therapeutics that Both Silence Specific Genes and Enhance Desired Immunostimulatory Effects -
CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication of a new study in Nature Medicine by scientists from the University of Bonn in collaboration with Alnylam. The new pioneering research documents t...See the full content of this document
Sponsored links
